AUTHORS
Aline Hatem, PhD, Cunqi Cui, PhD2, Zi Yan3, Shouping Zhang4, Eric Bouhassira, PhD5
AFFILIATIONS
1 Albert Einstein College of Medicine, Bronx, New York, United States
2 Albert Einstein College of Medicine, Bronx, New York, United States
3 Albert Einstein College of Medicine, Bronx, New York, United States
4 Albert Einstein College of Medicine, Bronx, New York, United States
5 Albert Einstein College of Medicine, Bronx, New York, United States
ABSTRACT
For more than a century, red blood cell (RBC) transfusion remains the standard treatment for anemia with more than 36,000 units of packed RBCs transfused in the USA each day. This demand has driven the development of lab-grown RBCs (lgRBCs) as a renewable alternative for transfusion and specialized diagnostic applications. However, scalable production remains challenging due to limited cell proliferative capacity and high manufacturing cost.
LgRBCs production relies on erythropoiesis, during which hematopoietic stem and progenitor cells (HSPCs) differentiate into mature, enucleated RBCs. A key determinant of scalable manufacturing is the generation and long-term maintenance of highly proliferative erythroid progenitors, referred to as self-renewing erythroblasts (SREs). We and others showed that constitutively activating mutations can maintain SREs in a proliferative state while reducing or eliminating their dependence on exogenous cytokines. In particular, our group previously generated human KIT-mutant SREs proliferating without stem cell factor (SCF).
DNA methyltransferase 3A (DNMT3A), a de novo DNA methyltransferase, is an epigenetic regulator of HSPC self-renewal, frequently mutated in clonal hematopoiesis. Recent studies suggest that DNMT3A may enhance cellular proliferative capacity by promoting telomerase activity and telomere maintenance. These observations raise the possibility that modulation of DNMT3A function could further improve the long-term expansion of SREs and enhance the scalability of lgRBC production.
In this study, we investigated the effects of DNMT3a Knock-out on the proliferation and phenotype of adult-derived SREs.
To investigate this hypothesis, we performed CRISPR-Cas9 editing of adult peripheral blood CD34+ HSPCs, cord blood CD34+ cells, and induced pluripotent stem cells (iPSCs), targeting either KIT alone or KIT in combination with DNMT3A, followed by ectopic expression of human telomerase reverse transcriptase (hTERT). Cumulative cell expansion was monitored throughout culture, and erythroid identity was confirmed by flow cytometric analysis of erythroid surface markers during late-stage proliferation. Cells were subsequently induced to undergo terminal differentiation to assess enucleation efficiency and globin expression. Genomic DNA was collected at multiple time points during expansion and analyzed by low-pass whole-genome sequencing to evaluate genomic integrity and estimate telomere length. Telomerase activity was measured using the TRAPeze™ XL Telomerase Detection Kit (Sigma-Aldrich). In parallel, next-generation sequencing of PCR amplicons spanning the edited KIT and DNMT3A loci was performed to quantify editing efficiency and monitor the frequency of edited alleles throughout culture.
In the absence of SCF, unedited control cells failed to expand beyond the early stages of culture. In contrast, KIT editing alone supported sustained proliferation of adult CD34+ cells, reaching a peak cumulative expansion of approximately 5 × 10⁴ cells by day 33 before gradually declining. Simultaneous knockout of KIT and DNMT3A produced a dramatic increase in proliferative capacity, with cumulative expansion exceeding 10⁹ cells by day 46—more than five orders of magnitude greater than that achieved with KIT editing alone. Ectopic expression of hTERT further extended proliferative capacity. Throughout expansion, the cells retained an erythroid progenitor phenotype, remaining positive for CD36, CD43, and CD71 until the final stages of culture. Upon differentiation, the cells generated adult-type RBCs with enucleation efficiencies exceeding 40% and expressed predominantly α- and β-globin, consistent with an adult erythroid phenotype.
Together, these findings demonstrate the successful generation of stable adult-derived self-renewing erythroblasts (SREs) with substantially enhanced proliferative capacity. Importantly, DNMT3A knockout markedly increased long-term expansion beyond that achieved by KIT activation alone while preserving erythroid identity, efficient terminal differentiation, and adult hemoglobin expression. These results identify DNMT3A as a novel regulator of erythroid self-renewal and provide a promising strategy for scalable manufacturing of cultured red blood cells (cRBCs). Future studies will investigate the molecular mechanisms by which DNMT3A loss promotes sustained proliferation and determine whether this approach can be further optimized for clinical-scale lgRBC production.
DISCLOSURES
Aline Hatem, PhD: No relevant conflicts of interest to declare.